A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

Inclusion Criteria: * Have a Type 1 Diabetes diagnosis for at least 6 months * Have been receiving insulin therapy via multiple daily injections or using an insulin pump and have been stable for at least 3 months prior to screening * Have a HbA1c level of ≤ 9.5% at screening * Have sufficient venous access for collection of blood samples * Have good general health, apart from their Type 1 diabetes, with no prior history of choanal atresia, nasal/pharyngeal blockage or nasal anomaly Exclusion Criteria: * Have a presence or history of glucagon hypersensitivity * Have a history of pheochromocytoma * Have a history of epilepsy or seizure disorder * Have 1 or more congenital anomalies to the anatomy of the nose, or require changes to the anatomy of the nose * Are using closed-loop insulin therapy, unless such a device is set to 'open loop/manual' mode on the day of the dosing visit * Have an episode of severe hypoglycemia or have had glucagon administered , during the 3 months prior to the screening visit and no severe hypoglycemia between the screening and dosing visit